SCHEMBL29282589

SCHEMBL29282589

CC1C(=O)N(c2ccc3c(c2)ncn3COCC[Si](C)(C)C)C1c1c(F)cc(-c2cnn(C)c2)cc1F

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ SIK1 P57059 3/20 0.35
▸ SIK2 Q9H0K1 3/20 0.35
▸ SIK3 Q9Y2K2 3/20 0.35
▸ ABL1 P00519 2/20 0.35
▸ CSF1R P07333 2/20 0.35
▸ LYN P07948 2/20 0.35
▸ PRKAB2 O43741 1/20 0.35
▸ TGFBR1 P36897 1/20 0.35
▸ TGFBR2 P37173 1/20 0.35
▸ PRKAG1 P54619 1/20 0.35
▸ PRKAA1 Q13131 1/20 0.35
▸ CHRM1 P11229 7/20 0.33
▸ FGFR1 P11362 5/20 0.33
▸ FLT1 P17948 1/20 0.33
▸ FGFR2 P21802 1/20 0.33
▸ FGFR4 P22455 1/20 0.33
▸ FGFR3 P22607 1/20 0.33
▸ FLT4 P35916 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30166775 1.00 BRD4 (0.37) BRD4CREBBPSIK1SIK2SIK3
SCHEMBL24815411 1.00 BRD4 (0.37) BRD4CREBBPSIK1SIK2SIK3
SCHEMBL25707208 1.00 BRD4 (0.37) BRD4CREBBPSIK1SIK2SIK3
SCHEMBL30455900 0.90 BRD4 (0.34) BRD4CREBBPFGFR1IDO1
SCHEMBL25707245 0.90 BRD4 (0.34) BRD4CREBBPFGFR1IDO1
SCHEMBL24816665 0.90 BRD4 (0.34) BRD4CREBBP
SCHEMBL29282600 0.90 BRD4 (0.34) BRD4CREBBPFGFR1IDO1
SCHEMBL30166841 0.90 BRD4 (0.34) BRD4CREBBP
SCHEMBL26833793 0.90 BRD4 (0.34) BRD4CREBBP
SCHEMBL24814386 0.87 BRD4 (0.37) BRD4CREBBPSIK1SIK2SIK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118019737-A Beta-lactam derivatives for the treatment of diseases 英矽智能科技知识产权有限公司 2024-05-10 — — CN disclosed
Send feedback